- Home
- EGY vs CMPS Comparison
EGY vs CMPS Comparison
Compare EGY & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- CMPS
- Stock Information
- Founded
- EGY 1985
- CMPS 2020
- Country
- EGY United States
- CMPS United Kingdom
- Employees
- EGY N/A
- CMPS N/A
- Industry
- EGY Oil & Gas Production
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- CMPS Health Care
- Exchange
- EGY Nasdaq
- CMPS Nasdaq
- Market Cap
- EGY 340.3M
- CMPS 364.9M
- IPO Year
- EGY N/A
- CMPS 2020
- Fundamental
- Price
- EGY $3.84
- CMPS $4.59
- Analyst Decision
- EGY
- CMPS Strong Buy
- Analyst Count
- EGY 0
- CMPS 7
- Target Price
- EGY N/A
- CMPS $18.83
- AVG Volume (30 Days)
- EGY 1.1M
- CMPS 1.7M
- Earning Date
- EGY 08-05-2025
- CMPS 07-31-2025
- Dividend Yield
- EGY 6.53%
- CMPS N/A
- EPS Growth
- EGY N/A
- CMPS N/A
- EPS
- EGY 0.56
- CMPS N/A
- Revenue
- EGY $489,162,000.00
- CMPS N/A
- Revenue This Year
- EGY N/A
- CMPS N/A
- Revenue Next Year
- EGY $24.62
- CMPS N/A
- P/E Ratio
- EGY $6.89
- CMPS N/A
- Revenue Growth
- EGY 3.02
- CMPS N/A
- 52 Week Low
- EGY $3.00
- CMPS $2.49
- 52 Week High
- EGY $7.43
- CMPS $8.54
- Technical
- Relative Strength Index (RSI)
- EGY 64.80
- CMPS 59.49
- Support Level
- EGY $3.30
- CMPS $4.33
- Resistance Level
- EGY $4.04
- CMPS $5.15
- Average True Range (ATR)
- EGY 0.15
- CMPS 0.38
- MACD
- EGY 0.05
- CMPS -0.01
- Stochastic Oscillator
- EGY 81.66
- CMPS 66.65
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.